The economic case for precision medicine

References

• Pearson E. Personalized medicine in diabetes: the role of ‘Omics’ and biomarkers. Diabet Med. 2016;33(6):712–717.
   PubMed Web of Science ®Google Scholar
• Trusheim M, Berndt E, Douglas F. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287–293.
   PubMed Web of Science ®Google Scholar
• Redekop W, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health. 2013;16(S6):S4–S9.
   PubMedGoogle Scholar
• Pashayan N, Pharoah P. Population-based screening in the era of genomics. Per Med. 2012;9(4):451–455.
   PubMed Web of Science ®Google Scholar
• Boycott K, Vanstone M, Bulman D, et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14(10):681–691.
   PubMed Web of Science ®Google Scholar
• Kaplan W, Wirtz V, Mantel-Teeuwisse A, et al. Priority medicines for europe and the world 2013 update. 1. Geneva: World Health Organization; 2013.
   Google Scholar
• Collins F, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
   PubMed Web of Science ®Google Scholar
• Rogowski W, Grosse S, Khoury M. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet. 2009;10(7):489–495.
   PubMed Web of Science ®Google Scholar
• Rogowski W, Hartz S, John J. Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Serv Res. 2008;8(194):1–12.
   PubMedGoogle Scholar
• Drummond M, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4. Oxford: Oxford University Press; 2015.
   Google Scholar
• Phillips K, van Bebber S. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. 2004;5(8):1139–1149.
   PubMed Web of Science ®Google Scholar
• Vegter S, Boersma C, Rozenbaum M, et al. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics. 2008;26(7):569–587.
   PubMed Web of Science ®Google Scholar
• Beaulieu M, De Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010;11(11):1573–1590.
   PubMed Web of Science ®Google Scholar
• Vegter S, Jansen E, Postma M, et al. Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. Drug Dev Res. 2010;71(8):492–501.
   Web of Science ®Google Scholar
• Wong W, Carlson J, Thariani R, et al. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics. 2010;28(11):1001–1013.
   PubMed Web of Science ®Google Scholar
• Hatz M, Schremser K, Rogowski W. Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics. 2014;32(5):443–455.
   PubMed Web of Science ®Google Scholar
• Berm E, De Looff M, Wilffert B, et al. Economic evaluation of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One. 2016;11(1):1–22.
   Web of Science ®Google Scholar
• Oosterhoff M, van der Maas M, Steuten L. A systematic review of health economic evaluations of diagnostic biomarkers. Appl Health Econ Health Policy. 2016;14(1):51–65.
   PubMed Web of Science ®Google Scholar
• Plumpton C, Roberts D, Pirmohamed M, et al. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. Pharmacoeconomics. 2016;34(8):771–793.
   PubMed Web of Science ®Google Scholar
• Payne K, Gavan S, Wright S, et al. Cost-effectiveness analyses of genetic and genomic diagnostic technologies. Nat Rev Genet. 2018; Forthcoming.
   Google Scholar
• Payne K, Eden M, Davison N, et al. Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions. Per Med. 2017;14(3):235–247.
   PubMed Web of Science ®Google Scholar
• Shabaruddin F, Fleeman N, Payne K. Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenomics Pers Med. 2015;2015(8):115–128.
   Google Scholar
• Rogowski W, Payne K, Schnell-Inderst P, et al. Concepts of ‘personalization’ in personalized medicine: implications for economic evaluation. Pharmacoeconomics. 2015;33(1):49–59.
   PubMed Web of Science ®Google Scholar
• Payne K, Annemans L. Reflections on market access for personalized medicine: recommendations for Europe. Value Health. 2013;16(S6):S32–S38.
   PubMedGoogle Scholar
• Annemans L, Redekop W, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health. 2013;16(S6):S20–S26.
   PubMedGoogle Scholar
• Payne K, Thompson A. Economics of pharmacogenomics: rethinking beyond QALYs? Curr Pharmgenomics Pers Med. 2013;11(3):187–195.
   Google Scholar
• Buchannan J, Wordsworth S, Schuh A. Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics. 2013;14(15):1833–1847.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Care Excellence; 2013. (NICE Process and Methods; PMG9).
   Google Scholar
• Culyer A. The rationing debate: maximising the health of the whole community. The case for. BMJ. 1997;314(7081):667–669.
   PubMedGoogle Scholar
• Claxton K, Martin S, Soares M, et al. Methods for the estimation of the national institute for health and care excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1–503.
   PubMed Web of Science ®Google Scholar
• Culyer A. Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. Health Econ Policy Law. 2016;11(4):415–432.
   PubMed Web of Science ®Google Scholar
• McCabe C, Claxton K, Culyer A. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733–744.
   PubMed Web of Science ®Google Scholar
• Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ. 1996;5(4):279–296.
   PubMed Web of Science ®Google Scholar
• Claxton K, Sculpher M, Culyer A. Mark Versus Luke? Appropriate methods for the evaluation of public health interventions. York: The University of York; 2007. ( (CHE Research Paper; 31)).
   Google Scholar
• Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341–364.
   PubMed Web of Science ®Google Scholar
• Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2):s68–s80.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Vol. 1. Oxford: Oxford University Press; 2006.
   Google Scholar
• Stevens W, Normand C. Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation. Soc Sci Med. 2004;58(2):315–320.
   PubMed Web of Science ®Google Scholar
• Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26(9):799–806.
   PubMed Web of Science ®Google Scholar
• Phelps C, Mushlin A. Focusing technology assessment using medical decision theory. Med Decis Making. 1988;8(4):279–289.
   PubMed Web of Science ®Google Scholar
• Coyle D, Buxton M, O’Brien B. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ. 2003;12(5):421–427.
   PubMed Web of Science ®Google Scholar
• Espinoza M, Manca A, Claxton K, et al. The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Making. 2014;34(8):951–964.
   PubMed Web of Science ®Google Scholar
• Black W. The CE plane: a graphical representation of cost-effectiveness. Med Decis Making. 1990;10(3):212–214.
   PubMed Web of Science ®Google Scholar
• Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2010;11(8):1343–1357.
   PubMed Web of Science ®Google Scholar
• Mok T, Wu Y, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.
   PubMed Web of Science ®Google Scholar
• Bogdanowicz B, Hoch M, Hartranft M. Flipped script for gefitinib: a reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer. J Oncol Pharm Pract. 2017;23(3):203–214.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. London: National Institute for Health and Care Excellence; 2010. (Technology Appraisal Guidance; TA192).
   Google Scholar
• Byron S, Crabb N, George E, et al. The health technology assessment of companion diagnostics: experience of NICE. Clin Cancer Res. 2014;20(6):1469–1476.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. London: National Institute for Health and Care Excellence; 2013. (Diagnostics Guidance; DG9).
   Google Scholar
• Garfield S, Polisena J, Spinner D, et al. Health technology assessment for molecular diagnostics: practices, challenges, and recommendations from the medical devices and diagnostics special interest group. Value Health. 2016;19(5):577–587.
   PubMed Web of Science ®Google Scholar
• Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics. 2000;17(5):445–459.
   PubMed Web of Science ®Google Scholar
• Sculpher M, Claxton K, Drummond M, et al. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7):677–687.
   PubMed Web of Science ®Google Scholar
• Buxton M, Drummond M, van Hout B, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6(3):217–227.
   PubMed Web of Science ®Google Scholar
• Westwood M, Joore M, Whiting P, et al. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18(32):1–166.
   Web of Science ®Google Scholar
• Lennard L. Implementation of TPMT Testing. Br J Clin Pharmacol. 2014;77(4):704–714.
   PubMed Web of Science ®Google Scholar
• Payne K, Newman W, Gurwitz D, et al. TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’? Per Med. 2009;6(1):103–113.
   PubMed Web of Science ®Google Scholar
• Thompson A, Newman W, Elliott R, et al. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health. 2014;17(1):22–33.
   PubMed Web of Science ®Google Scholar
• Newman W, Payne K, Tricker K, et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics. 2011;12(6):815–826.
   PubMed Web of Science ®Google Scholar
• Garrison L, Austin M. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Affairs. 2006;25(5):1281–1290.
   Web of Science ®Google Scholar
• Payne K, Fargher E, Roberts S, et al. Valuing pharmacogenetic testing services: a comparison of patients’ and health care professionals’ preferences. Value Health. 2011;14(1):121–134.
   PubMed Web of Science ®Google Scholar
• Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med Decis Making. 2008;28(1):21–32.
   PubMed Web of Science ®Google Scholar
• Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002;2(5):364–371.
   PubMed Web of Science ®Google Scholar
• Touw D, Neef C, Thomson A, et al. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit. 2005;27(1):10–17.
   PubMed Web of Science ®Google Scholar
• Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;73(1):1947–1955.
   Google Scholar
• Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24(3):306–311.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Warren R, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheum. 2015;67(8):2011–2019.
   PubMed Web of Science ®Google Scholar
• Vincent F, Morand E, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–178.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Therapeutic monitoring of TNF-alpha inhibitors in crohn’s disease (LISA-TRACKER ELISA Kits, IDKmonitor ELISA Kits, and promonitor ELISA Kits). London: National Institute for Health and Care Excellence; 2016. (Diagnostics Guidance; DG22).
   Google Scholar
• Roberts M, Russell L, Paltiel D, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Value Health. 2012;15(6):804–811.
   PubMed Web of Science ®Google Scholar
• Tappenden P. Problem structuring for health economic model development. In: Culyer A, editor. Encyclopedia of health economics. Vol. 3. 1 ed. Oxford: Elsevier; 2014. p. 168–179.
   Google Scholar
• Jani M, Gavan S, Dixon W, et al. A microcosting study of immunogenicity and TNFi drug level tests for therapeutic monitoring in clinical practice. Rheumatology. 2016;55(12):2131–2137.
   PubMed Web of Science ®Google Scholar
• Davies W, Downes S, Fu J, et al. Next-generation sequencing in health-care delivery: lessons from the functional analysis of rhodopsin. Genet Med. 2012;14(11):891–899.
   PubMed Web of Science ®Google Scholar
• Harrison M, Birch S, Eden M, et al. Variation in healthcare services for specialist genetic testing and implications for planning genetic services: the example of inherited retinal dystrophy in the english NHS. J Community Genet. 2015;6(2):157–165.
   PubMed Web of Science ®Google Scholar
• O’Sullivan J, Mullaney B, Bhaskar S, et al. A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. J Med Genet. 2012;49(5):322–326.
   PubMed Web of Science ®Google Scholar
• UK Genetic Testing Network. Gene Dossier: retinal degeneration disorders 105 gene panel. London: UK Genetic Testing Network; 2012.
   Google Scholar
• Salleh S, Thokala P, Brennan A, et al. Discrete event simulation-based resource modelling in health technology assessment. Pharmacoeconomics. 2017;35(10):989–1006.
   PubMed Web of Science ®Google Scholar
• Combs R, Hall G, Payne K, et al. Understanding the expectations of patients with inherited retinal dystrophies. Br J Ophthalmol. 2013;97(8):1057–1061.
   PubMed Web of Science ®Google Scholar
• Samiy N. Gene therapy for retinal diseases. J Ophthalmic Vis Res. 2014;9(4):506–509.
   PubMedGoogle Scholar
• Payne K, McAllister M, Davies L. Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ. 2013;22(3):258–271.
   PubMed Web of Science ®Google Scholar
• Sculpher M, Claxton K, Pearson S. Developing a value framework: the need to reflect the opportunity costs of funding decisions. Value Health. 2017;20(2):234–239.
   PubMed Web of Science ®Google Scholar
• Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics. 2008;26(9):781–798.
   PubMed Web of Science ®Google Scholar
• Griffin S, Claxton K, Palmer S, et al. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ. 2011;20(2):212–224.
   PubMed Web of Science ®Google Scholar
• Stevenson M, Tappenden P, Squires H. Methods for handling uncertainty within pharmaceutical funding decisions. Int J Syst Sci. 2014;45(1):60–68.
   Web of Science ®Google Scholar
• Neumann P, Sanders G, Russell L, et al. Cost-effectiveness in health and medicine. Vol. 2. Oxford: Oxford University Press; 2017
   Google Scholar
• Brennan A, Chick S, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–1310.
   PubMed Web of Science ®Google Scholar
• Bojke L, Claxton K, Sculpher M, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health. 2009;12(5):739–749.
   PubMed Web of Science ®Google Scholar
• Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14(4):339–347.
   PubMed Web of Science ®Google Scholar
• Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479–500.
   PubMed Web of Science ®Google Scholar
• Wilson E. A practical guide to value of information analysis. Pharmacoeconomics. 2015;33(2):105–121.
   PubMed Web of Science ®Google Scholar
• Claxton K, Ginnelly L, Sculpher M, et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS technology assessment programme. Health Technol Assess. 2004;8(31):1–118.
   PubMed Web of Science ®Google Scholar
• Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5(6):513–524.
   PubMed Web of Science ®Google Scholar
• Sculpher M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy. 1997;2(1):26–30.
   PubMedGoogle Scholar
• Annemans L, Genesté B, Jolain B. Early modelling for assessing health and economic outcomes of drug therapy. Value Health. 2000;3(6):427–434.
   PubMedGoogle Scholar
• Steuten L, Ramsey S. Improving early cycle economic evaluation of diagnostic technologies. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):491–498.
   PubMed Web of Science ®Google Scholar
• Buisman L, Rutten-Van Mölken M, Postmus D, et al. The early bird catches the worm: early cost-effectiveness analysis of new medical tests. Int J Technol Assess Health Care. 2016;32(1–2):46–53.
   PubMed Web of Science ®Google Scholar
• Pohlhaus J, Cook-Deegan R. Genomics research: world survey of public funding. BMC Genomics. 2008;9(472):1–18.
   PubMedGoogle Scholar
• Claxton K, Sculpher M. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24(11):1055–1068.
   PubMed Web of Science ®Google Scholar
• Genome Canada. Genomics: discovery, impact, success - Genome Canada Strategic Plan 2012-2017. Ottawa, ON: Genome Canada; 2012.
   Google Scholar